6470-18-4Relevant articles and documents
Method for preparing 8-acetamido-2-naphthol
-
Paragraph 0025; 0026, (2018/04/27)
The invention provides a method for preparing 8-acetamido-2-naphthol and belongs to the technical field of compound preparation methods. The preparation method comprises the following steps: 8-amino-2-naphthalene sulfonic acid and alkali metal hydroxides according to a molar ratio of 1:(3-12), mixing with an organic solvent in an autoclave, and performing alkali fusion at the temperature of 160-320 DEG C and the pressure of 0-1.5MPa so as to prepare 8-amino-2-naphthol; and recovering the organic solvent from the prepared reactants, carrying out an amidation reaction on the prepared 8-amino-2-naphthol and acetic acid or acetic anhydride at the reaction temperature of 20-40 DEG C so as to obtain 8-acetamido-2-naphthol, performing suction filtration, pressing to dry, thereby obtaining the 8-acetamido-2-naphthol. The preparation method is simple in process, less by-products are produced in the reaction, the sulfonate purity is high, the high-purity 8-acetamido-2-naphthol can be directly prepared by alkali fusion without refining, the production cost is reduced, lots of acidic wastewater is not produced, and the environmental protection is facilitated.
The development of a short route to the API ropinirole hydrochloride
Yousuf, Zeshan,Richards, Andrew K.,Dwyer, Andrew N.,Linclau, Bruno,Harrowven, David C.
, p. 10532 - 10539 (2015/11/10)
A four-step, three-stage synthesis of the API ropinirole hydrochloride has been developed from a commercially available naphthalene derivative. The new route has half the step-count and twice the overall yield of the current manufacturing process. Key features of the synthesis are a regioselective Birch reduction and an ozonolysis with concomitant ring closure to induce the required ring contraction.
New compounds with antiglutamatergic properties and uses thereof
-
Page/Page column 13, (2008/12/08)
The present invention provides new compounds displaying antiglutamatergic properties. It also provides the use of such compounds for the treatment and/or prophylaxis of conditions and diseases linked to abnormalities in glutamatergic transmission. It further provides a pharmaceutical composition for the treatment and/or prophylaxis of acute and chronic neurodegenerative conditions and disorders.
ERβ ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ERβ selectivity
Mewshaw, Richard E.,Edsall Jr., Richard J.,Yang, Cuijian,Manas, Eric S.,Xu, Zhang B.,Henderson, Ruth A.,Keith Jr., James C.,Harris, Heather A.
, p. 3953 - 3979 (2007/10/03)
The 2-phenylnaphthalene scaffold was explored as a simplified version of genistein in order to identify ER selective ligands. With the aid of docking studies, positions 1, 4, and 8 of the 2-phenylnaphthalene template were predicted to be the most potentially influential positions to enhance ER selectivity using two different binding orientations. Both orientations have the phenol moiety mimicking the A-ring of genistein. Several compounds predicted to adopt orientations similar to that of genistein when bound to ERβ were observed to have slightly higher ER affinity and selectivity than genistein. The second orientation we exploited, which was different from that of genistein when bound to ERβ, resulted in the discovery of several compounds that had superior ER selectivity and affinity versus genistein. X-ray structures of two ER selective compounds (i.e., 15 and 47) confirmed the alternate binding mode and suggested that substituents at positions 1 and 8 were responsible for inducing selectivity. One compound (i.e., 47, WAY-202196) was further examined and found to be effective in two models of inflammation, suggesting that targeting ER may be therapeutically useful in treating certain chronic inflammatory diseases.
Synthesis of HKI 0231B
Scopton, Alex,Kelly, T. Ross
, p. 10004 - 10012 (2007/10/03)
The total synthesis of HKI 0231B (1b) was completed in 12 linear steps and 15.6% overall yield. An unusual anionic cyclization provided access to intermediate 61 and the embedded benz[cd]-indol-3-(1H)-one ring system 3. Directed ortho-lithiation in the presence of a ketone followed by formylation and finally acid-catalyzed methanolysis complete the synthesis. Studies directed toward the construction and reactivity of the lactam acetal functionality present in HKI 0231A (1a) are also reported.
Characterization of the 5-HT7 Receptor. Determination of the Pharmacophore for 5-HT7 Receptor Agonism and CoMFA-Based Modeling of the Agonist Binding Site
Vermeulen, Erik S.,Schmidt, Anne W.,Sprouse, Jeffrey S.,Wikstr?m, H?kan V.,Grol, Cor J.
, p. 5365 - 5374 (2007/10/03)
On the basis of a set of 20 diverse 5-HT7 receptor agonists, the pharmacophore for 5-HT7 receptor agonism was determined. Additionally two CoMFA models were developed, based on different alignments of the agonists. Both models show good correlations between experimental and predictive pKi values and show a high degree of similarity. The CoMFA fields were subsequently used to map the agonist binding site of the model of the 5-HT7 receptor. Important roles in ligand binding are attributed to Asp162 of TM3 (interaction with a protonated nitrogen), and Thr244 of TM5 (interaction with a substituent at an aromatic moiety). Amino acid residues of the aromatic cluster of TM6 are hypothesized to play an important role in ligand binding as π-π stacking moieties. Agonists missing a hydrogen-bond-accepting moiety, but possessing an aromatic substituent instead, seem to bind the receptor with high affinity as well by occupying a lipophilic pocket hosted by residues of TM5 and TM6.
Substituted phenyl naphthalenes as estrogenic agents
-
, (2008/06/13)
This invention provides estrogen receptor modulators of formula I, having the structure 1wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10, are as defined in the specification, or a pharmaceutically acceptable salt thereof.
1-[2-(1H-INDEN-3-YL)ETHYL]-4-(NAPHTH-1-YL)PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS
-
, (2008/06/13)
Compounds of formula: STR1 in which X represents a hydrogen atom, a C 1-C 3 alkoxy group or a cyclopropylmethoxy group and Y represents a hydrogen atom or a methoxy group, are useful in the therapy of conditions.
